Vemurafenib and dabrafenib are selective BRAF inhibitors that have transformed the treatment landscape for patients with BRAF^V600E mutant melanoma, resulting in improved rates of response and overall survival.286 Their development underscores the importance of personalized medicine in oncology. The gene discussed is BRAF; the disease is melanoma.